# **Data Changes for the CCDD OCTOBER Release Candidate 2023**

## **Based on the QA Release Generation** 20231004

|  |  |
| --- | --- |
| Data entered by | A.Raghuveer |
| Data checked by | J.Hutsul |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
| 8002285 | octocog alfa | 580ebbed98a53b6f41333d5afa203289 |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8002400 | Ad26.COV2.S (recombinant) |
| 8001756 | docosanol |
| 8001079 | eprosartan |
| 8001080 | eprosartan and hydrochlorothiazide |
| 8001971 | trametinib |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  |  |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9014633 | Ad26.COV2.S (recombinant) 5e10 vp per 0.5 mL suspension for injection 2.5 mL vial |
| 9004072 | docosanol 10 % cutaneous cream |
| 9003368 | efavirenz 200 mg oral capsule |
| 9003369 | efavirenz 50 mg oral capsule |
| 9013958 | enasidenib (enasidenib mesylate) 100 mg oral tablet |
| 9003521 | eprosartan (eprosartan mesylate) 400 mg oral tablet |
| 9003923 | eprosartan (eprosartan mesylate) 600 mg and hydrochlorothiazide 12.5 mg oral tablet |
| 9003601 | eprosartan (eprosartan mesylate) 600 mg oral tablet |
| 9012721 | insulin human 40 unit per mL and insulin isophane human 60 unit per mL suspension for injection 3 mL cartridge |
| 9000263 | morphine sulfate 50 mg oral tablet |
| 9000944 | oxybutynin chloride 5 mg prolonged-release oral tablet |
| 9014556 | risperidone 120 mg per syringe powder for prolonged-release suspension for injection with diluent solution syringe |
| 9014557 | risperidone 90 mg per syringe powder for prolonged-release suspension for injection with diluent solution syringe |
| 9005316 | trametinib 0.5 mg oral tablet |
| 9005317 | trametinib 2 mg oral tablet |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For all DINs, they have had additional UoP added. All products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| NA | 2245677 | ABREVA (docosanol 10 % cutaneous cream) GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC | Canceled (not a drug) |
| 95352 | 2465329 | ALTA-DOCUSATE SODIUM (docusate sodium 100 mg oral capsule) ALTAMED PHARMA | Canceled post-market Expiry 2023.09.30 |
| 85715 | 2372029 | ANTIBIOTIC CREAM (gramicidin 0.25 mg per g and polymyxin B (polymyxin B sulfate) 10000 unit per g cutaneous cream) CANADIAN CUSTOM PACKAGING COMPANY | Canceled post-market Expiry 2023.09.30 |
| 85717 | 2372045 | ANTIBIOTIC CREAM PLUS PAIN RELIEF (gramicidin 0.25 mg per g and lidocaine hydrochloride 40 mg per g and polymyxin B (polymyxin B sulfate) 10000 unit per g cutaneous cream) CANADIAN CUSTOM PACKAGING COMPANY | Canceled post-market Expiry 2023.09.30 |
| 9908 | 828866 | CEPHALEXIN-500 (cephalexin (cephalexin monohydrate) 500 mg oral tablet) PRO DOC LIMITEE | Canceled post-market Expiry 2023.09.30 |
| 67698 | 2243763 | COMTAN (entacapone 200 mg oral tablet) SANDOZ CANADA INCORPORATED | Dormant 2023.09.08 |
| 67903 | 2243960 | DITROPAN XL (oxybutynin chloride 5 mg prolonged-release oral tablet) JANSSEN INC | Canceled post-market Expiry 2023.09.30 |
| 95559 | 2467208 | DOVE DERMA+CARE SCALP ANTI-DANDRUFF SMOOTHING MOISTURE (pyrithione zinc 1 % shampoo) UNILEVER CANADA | Canceled post-market Expiry 2023.09.17 |
| 77258 | 2287145 | FOSRENOL (lanthanum (lanthanum carbonate hydrate) 250 mg chewable tablet) TAKEDA CANADA INC | Canceled post-market Expiry 2023.09.30 |
| 97568 | 2485435 | IDHIFA (enasidenib (enasidenib mesylate) 100 mg oral tablet) CELGENE INC | Canceled post-market Expiry 2023.09.30 |
| 100239 | 2513153 | JCOVDEN (Ad26.COV2.S (recombinant) 5e10 vp per 0.5 mL suspension for injection 2.5 mL vial) JANSSEN INC | Canceled post-market Expiry 2023.09.30 |
| 83667 | 2351404 | METOPROLOL SR (metoprolol tartrate 100 mg prolonged-release oral tablet) PRO DOC LIMITEE | Canceled post-market Expiry 2023.09.30 |
| 14262 | 2024314 | NOVOLIN GE 40/60 PENFILL (insulin human 40 unit per mL and insulin isophane human 60 unit per mL suspension for injection 3 mL cartridge) NOVO NORDISK CANADA INC | Canceled post-market Expiry 2023.09.30 |
| 99722 | 2507846 | PERSERIS (risperidone 120 mg per syringe powder for prolonged-release suspension for injection with diluent solution syringe) HLS THERAPEUTICS INC | Dormant 2022.06.16 |
| 99721 | 2507838 | PERSERIS (risperidone 90 mg per syringe powder for prolonged-release suspension for injection with diluent solution syringe) HLS THERAPEUTICS INC | Dormant 2022.06.16 |
| 11011 | 783900 | PMS-DEXAMETHASONE SOD PHOSPHATE INJ 10MG/ML (dexamethasone phosphate (dexamethasone sodium phosphate) 100 mg per 10 mL solution for injection vial) PHARMASCIENCE INC | Canceled post-market Expiry 2023.10.01 |
| 98018 | 2490110 | PRIVA-AMITRIPTYLINE (amitriptyline hydrochloride 10 mg oral tablet) PHARMAPAR INC | Canceled post-market Expiry 2023.09.30 |
| 98019 | 2490129 | PRIVA-AMITRIPTYLINE (amitriptyline hydrochloride 25 mg oral tablet) PHARMAPAR INC | Canceled post-market Expiry 2023.09.30 |
| 98020 | 2490137 | PRIVA-AMITRIPTYLINE (amitriptyline hydrochloride 50 mg oral tablet) PHARMAPAR INC | Canceled post-market Expiry 2023.09.30 |
| 98021 | 2490145 | PRIVA-AMITRIPTYLINE (amitriptyline hydrochloride 75 mg oral tablet) PHARMAPAR INC | Canceled post-market Expiry 2023.09.30 |
| 13494 | 1934740 | ROBITUSSIN AC (codeine phosphate 10 mg per 5 mL and guaifenesin 100 mg per 5 mL and pheniramine maleate 7.5 mg per 5 mL syrup) GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC | Canceled post-market 2023.09.14 |
| 6757 | 675962 | STATEX TABLETS 50MG (morphine sulfate 50 mg oral tablet) PALADIN LABS INC. | Canceled post-market Expiry 2023.09.30 |
| 92489 | 2440520 | STUBBORN ACNE DAILY LEAVE-ON MASK (benzoyl peroxide 2.5 % cutaneous gel) JOHNSON & JOHNSON INC | Canceled post-market Expiry 2023.09.30 |
| 63376 | 2239888 | SUSTIVA 200MG (efavirenz 200 mg oral capsule) BRISTOL-MYERS SQUIBB CANADA | Canceled post-market Expiry 2023.09.30 |
| 63374 | 2239886 | SUSTIVA 50MG (efavirenz 50 mg oral capsule) BRISTOL-MYERS SQUIBB CANADA | Canceled post-market Expiry 2023.09.30 |
| 63981 | 2240432 | TEVETEN (eprosartan (eprosartan mesylate) 400 mg oral tablet) BGP PHARMA ULC | Canceled post-market 2023.09.18 |
| 67885 | 2243942 | TEVETEN (eprosartan (eprosartan mesylate) 600 mg oral tablet) BGP PHARMA ULC | Canceled post-market 2023.09.18 |
| 73859 | 2253631 | TEVETEN PLUS (eprosartan (eprosartan mesylate) 600 mg and hydrochlorothiazide 12.5 mg oral tablet) BGP PHARMA ULC | Canceled post-market 2023.09.18 |

The following changes have been made to the Exclusion List for the SEPTEMBER 2023 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Exclusion List
* ADD to Exclusion List
* REMOVE from Exclusion List

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 1e59bbe7f53aff9a8c392c71b6e8fb01 | valganciclovir (valganciclovir hydrochloride) 50 mg per mL powder for oral solution | 102433 | 02535483 | AURO-VALGANCICLOVIR (valganciclovir (valganciclovir hydrochloride) 50 mg per mL powder for oral solution) AURO PHARMA INC | ADD |
| 8b735a76787878b098ff48fd2741b39a | clevidipine 0.5 mg per mL emulsion for injection | 85108 | 02366223 | CLEVIPREX (clevidipine 0.5 mg per mL emulsion for injection) CHIESI FARMACEUTICI S.P.A. | ADD |